Embecta Corp.

NASDAQ:EMBC

Drug Manufacturers - Specialty & Generic

Healthcare
$6.09 +0.65%

+$0.02 today

Market cap
$345.06M
Beta
0.81
P/E (TTM)
1.6
EPS (TTM)
$1.92
Dividend yield
14.79%
52W Low $2.77High $15.55

Volume 0.72M

Average 1.95M

EMBC Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Embecta Corp.NASDAQ: EMBC

Net Margin · Q2 FY2026 · quarter ended Mar 2026

Net margin narrows to -1.8%

Net margin was -1.8% in Q2 FY2026, down 10.9 pp from a year earlier. On a trailing-twelve-month basis it was 10.7%, up 5.9 pp year over year. Over 3 fiscal years it narrowed by 11.0 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 3 analysts of 10.5% for the fiscal year ending Sep 2026, up from 8.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-1.8%-18.7 pp QoQ
Last fiscal yearSep 2025
8.8%+1.9 pp YoY
LTMMar 2026
10.7%+5.9 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-10.9 pp-9.3 pp+1.6 pp
1 year+1.9 pp+1.7 pp-0.2 pp
3 years-11.0 pp+1.0 pp+12.0 pp
5 years+7.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
8.8%
Year-over-year change
+1.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How EMBC compares with its peers on the latest reported figures

  • EMBC's LTM Mar 2026 net margin of 10.7% is the 3rd highest of the 11 companies compared; the peer median is -42.7%.
  • Its year-over-year change of +5.9 pp is the 6th highest of 11, against a peer median of -4.8 pp.
  • Over three fiscal years its change of -11.0 pp compares with a peer median of -27.5 pp.
EMBC Competitors Peer median
Net Margin for EMBC and competitors
Company Period LTM level YoY 3-year change
CDNACareDx, IncLTM Jun 202624.2% +9.1 pp+18.2 pp
SIGASIGA Technologies, Inc.LTM Mar 202621.6% -18.7 pp-6.0 pp
EMBCEmbecta Corp.LTM Mar 202610.7% +5.9 pp-11.0 pp
EBSEmergent BioSolutions Inc.LTM Mar 2026-1.3% +12.4 pp+26.0 pp
EVHEvolent Health, Inc.LTM Mar 2026-26.3% -21.7 pp-27.1 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-37.1% +53.1 pp-95.3 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-48.2% -36.0 pp-27.9 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-137.1% -37.1 pp-74.0 pp
PSNLPersonalis, Inc.LTM Mar 2026-148.1% -50.0 pp—
VIRVir Biotechnology, Inc.LTM Mar 2026-676.0% +2093.1 pp-670.8 pp
PRMEPrime Medicine, Inc.LTM Mar 2026-4917.6% +334.9 pp—
Peer median (excluding EMBC) -42.7%-4.8 pp-27.5 pp

Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue1.17B1.13B1.12B1.12B1.08B
Cost of Revenue365M354.6M370.9M394.2M400.9M
Gross Profit800M774.9M749.9M728.9M679.5M
Gross Margin68.7%68.6%66.9%64.9%62.9%
Research & Development63M65M85.2M78.8M21.5M
Selling, General & Admin240.3M294.8M341.3M365.1M331.4M
Operating Expenses308M396.8M520.3M554.7M350.2M
Depreciation & Amortization38M31.7M32.7M42.5M51.1M
EBITDA533M334.5M245.4M199M294.7M
EBITDA Margin45.8%29.6%21.9%17.7%27.3%
Operating Income492M378.1M229.6M174.2M329.3M
Operating Margin42.2%33.5%20.5%15.5%30.5%
Interest Income00000
Interest Expense046.2M107M112.3M107.3M
Other Income / Expenses3M(121.5M)(123.9M)(130M)(193M)
Income Before Tax495M256.6M105.7M44.2M136.3M
Pre-Tax Margin42.5%22.7%9.4%3.9%12.6%
Income Tax Expense80M33M35.3M(34.1M)40.9M
Net Income414.8M223.6M70.4M78.3M95.4M
Net Margin35.6%19.8%6.3%7.0%8.8%
EPS (Basic)7.313.921.231.361.64
EPS (Diluted)7.313.891.221.341.62
Weighted Avg Shares56.8M57.06M57.24M58.43M58.31M
Weighted Avg Shares (Diluted)56.8M57.06M57.76M58.33M58.92M

Embecta Corp.

NASDAQ:EMBC

Intrinsic Alpha fair value

Locked

Current Price

$6.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.